Key Takeaways:
- Geron Corporation (GERN, Financial) has faced notable stock volatility, with a 58.89% decline over the past year.
- Wall Street analysts predict a significant potential upside based on current price targets.
- GuruFocus metrics suggest a remarkable upside potential for GERN, indicating substantial growth opportunities.
Geron Corporation (GERN), a commercial-stage biopharmaceutical company, has had a turbulent year marked by a significant 58.89% drop in its stock price over the past 52 weeks. As of April 7, 2025, the stock concluded trading at $1.41, with a market capitalization of $898.035 million. Investors are keenly observing GERN as it maneuvers through the current market volatility.
Wall Street Analysts' Price Target Projections
Wall Street analysts have provided a positive outlook for Geron Corp (GERN, Financial), with one-year price targets from 8 analysts averaging $4.50. The high estimate stands at $7.00, while the low estimate is $2.00. This projection implies an impressive upside of 226.09% from the current price of $1.38. For more in-depth estimates, visit the Geron Corp (GERN) Forecast page.
Brokerage Recommendation and Analyst Ratings
The consensus recommendation from 9 brokerage firms for Geron Corp (GERN, Financial) is an average rating of 1.9, categorized as "Outperform." The rating framework spans from 1, suggesting a Strong Buy, to 5, which corresponds to Sell. This rating reflects a favorable outlook from analysts, indicating a potential for outperformance in the market.
Evaluating GF Value and Potential Growth
According to GuruFocus, the estimated GF Value for Geron Corp (GERN, Financial) one year from now is projected at $375.49. This estimation suggests an extraordinary upside of 27109.42% from the current price of $1.38. GF Value represents GuruFocus’ assessment of the fair trading value of the stock, derived from historical trading multiples, past business growth, and anticipated future performance. For further details, explore the Geron Corp (GERN) Summary page.
With significant potential upsides and a strong recommendation from analysts, investors are closely monitoring Geron Corporation as it strives to make a mark in the biopharmaceutical sector.
